🚀 Institutions taking big swings on #UnusualOptionsActivity with short expirations! Weekly Top Unu

🚀 Institutions taking big swings on #UnusualOptionsActivity with short expirations!

Weekly Top Unusual Activity from 🔥 INSIDERFINANCE.COM 🔥
1. #SLS 50% OTM
2. #COHR 46% OTM
3. #FRMI 42% OTM
4. #CMTL 42% OTM
5. #IDYA 38% OTM

#OptionFlow #OptionsTrading #Trading

🎯 #UnusualOptionsActivity trade ideas! Strong census from institutions on #options with short expir

🎯 #UnusualOptionsActivity trade ideas! Strong census from institutions on #options with short expirations.

PM Algo #TradeIdea from 🔥 INSIDERFINANCE.COM 🔥
#COHR, #IDYA, #CLF, #CVNA, #RIVN

#OptionFlow #OptionsTrading #Trading

🚀 Institutions taking big swings on #UnusualOptionsActivity with short expirations! PM Top Unusual

🚀 Institutions taking big swings on #UnusualOptionsActivity with short expirations!

PM Top Unusual Activity from 🔥 INSIDERFINANCE.COM 🔥
1. #COHR 46% OTM
2. #PL 42% OTM
3. #IDYA 38% OTM
4. #RGTI 37% OTM
5. #AMD 36% OTM

#OptionFlow #OptionsTrading #Trading

Biocytogen Announces Clinical Milestone with First Patient Dosed in Phase 1 Trial of IDEAYA’s First-in-Class B7H3/PTK7 Bispecific TOP1 ADC IDE034 Biocytogen announced that partner IDEAYA (Nasdaq: IDYA) dosed the first patient in the Phase 1 trial of IDE034, a first-in-class B7H3/PTK7 bispecific TOP1 ADC.First dosing triggers a $5 million milestone payment to Biocytogen under the companies' July 2024 license agreement. The Phase 1 study will evaluate safety, tolerability, and PK, with planned combination testing including IDEAYA's oral PARG inhibitor IDE161.

#IDYA Biocytogen Announces Clinical Milestone with First Patient Dosed in Phase 1 Trial of IDEAYA’s First-in-Class B7H3/PTK7 Bispecific TOP1 ADC IDE034

www.stocktitan.net/news/IDYA/biocytogen-ann...

JUST IN: ( NASDAQ: #IDYA ) IDEAYA Biosciences Provides a Business Update and Outlines 2026 Corporate Objectives at the 44th Annual J.P. Morgan Healthcare Conference

IDEAYA Biosciences Provides a Business Update and Outlines 2026 Corporate Objectives at the 44th Annual J.P. Morgan Healthcare Conference IDEAYA Biosciences (NASDAQ: IDYA) outlined 2026 objectives focused on advancing registrational trials, ADC+DDR combinations, MTAP-pathway programs and next-generation therapies. Key milestones include topline PFS results from the Phase 2/3 OptimUM-02 darovasertib+crizotinib trial in Q1 2026 that could enable a potential accelerated approval, initiation or enrollment milestones across multiple darovasertib Phase 3 trials by H1 2026, IND clearance for IDE574 in January 2026 with a planned Phase 1 start in Q1 2026, and multiple INDs/starts for IDE034, IDE161, IDE892, IDE397 and IDE849 through 2026. The company reported approximately $1.1 billion in cash and marketable securities as of 9/30/25, expected to fund operations into 2030.

#IDYA IDEAYA Biosciences Provides a Business Update and Outlines 2026 Corporate Objectives at the 44th Annual J.P. Morgan Healthcare Conference

www.stocktitan.net/news/IDYA/ideaya-bioscie...

IDE034, a Bispecific ADC Licensed by Biocytogen to IDEAYA, Receives FDA IND Clearance Biocytogen Pharmaceuticals Co., Ltd., announced that its partner IDEAYA Biosciences, Inc., a precision oncology company, has received the clearance of an investigational new drug application with the U.S. Food and Drug Administration for the initiation of a Phase 1 clinical trial of IDE034, a potential first-in-class B7H3/PTK7 bispecific antibody-drug...

#IDYA IDE034, a Bispecific ADC Licensed by Biocytogen to IDEAYA, Receives FDA IND Clearance

www.stocktitan.net/news/IDYA/ide034-a-bispe...

IDEAYA Biosciences Announces Positive Data From Phase 1/2 Combination Trial of IDE397, a potential first-in-class MAT2A inhibitor, and Trodelvy® in MTAP-Deletion Urothelial Cancer Overall response rate of 57% in patients treated with a combination of 30 mg IDE397 plus 7.5 mg/kg Trodelvy ®; ORR of 33% at 15 mg IDE397 plus 10 mg/kg Trodelvy ® Manageable safety profile at both expansion doses, consistent with known adverse events observed with each agent alone, with no treatment related serious adverse events observed at the IDE397 30 mg...

#IDYA IDEAYA Biosciences Announces Positive Data From Phase 1/2 Combination Trial of IDE397, a potential first-in-class MAT2A inhibitor, and Trodelvy® in MTAP-Deletion Urothelial Cancer

www.stocktitan.net/news/IDYA/ideaya-bioscie...

IDEAYA Biosciences Announces Positive Interim Phase 2 Data for Darovasertib in the Neoadjuvant Setting of Primary Uveal Melanoma IDEAYA Biosciences (Nasdaq: IDYA) announced positive interim Phase 2 data for darovasertib in treating primary uveal melanoma (UM). The drug showed impressive results in the neoadjuvant setting, with 76% of patients achieving ≥20% ocular tumor shrinkage. Key findings include 48% of patients achieving ≥20% reduction in simulated radiation dose to key visual structures and 65% of patients showing visual improvement during treatment.The Phase 2 OptimUM-09 trial evaluated 39 patients for safety and 21 for efficacy. Darovasertib demonstrated a manageable safety profile with mostly Grade 1 and 2 treatment-related adverse events, though approximately 10% experienced Grade 3 or higher events. The company has initiated a Phase 3 registration-enabling OptimUM-10 trial during Q2 2025.

#IDYA IDEAYA Biosciences Announces Positive Interim Phase 2 Data for Darovasertib in the Neoadjuvant Setting of Primary Uveal Melanoma

www.stocktitan.net/news/IDYA/ideaya-bioscie...

Novel PRMT5 Inhibitor Targets 15-20% of Lung Cancer Patients: IDEAYA's IDE892 Advances to Clinical Stage IDEAYA Biosciences advances IDE892 for MTAP-deleted lung cancer, targeting Phase 1 trial in Q4 2025. Drug shows potential synergy with IDE397 MAT2A inhibitor for 15-20% of NSCLC patients.

#IDYA IDEAYA Biosciences Announces IND Submission for IDE892, a Potential Best-In-Class PRMT5 Inhibitor for MTAP-Deletion Solid Tumors

www.stocktitan.net/news/IDYA/ideaya-bioscie...

$530 Million Deal: IDEAYA's Breakthrough Eye Cancer Drug Darovasertib Gets Global Partnership with Servier IDEAYA receives $210M upfront, up to $320M in milestones for ex-US rights to darovasertib in uveal melanoma. Phase 3 trials planned across neoadjuvant, adjuvant and metastatic settings.

#IDYA Servier and IDEAYA Biosciences Partner to Bring Darovasertib, a Promising Uveal Melanoma Treatment, to Patients Worldwide

www.stocktitan.net/news/IDYA/servier-and-id...

IDEAYA (IDYA) Q2 Net Loss Improves 27% | The Motley Fool

#IDYA #8001d86f-7d7b-4c61-b2d9-2c6b2108d409 #data-news

Origin | Interest | Match

IDEAYA Biosciences Announces Proffered Paper Oral Presentation at ESMO 2025 for Phase 2 Clinical Trial of Neoadjuvant Darovasertib in Primary Uveal Melanoma IDEAYA Biosciences (NASDAQ:IDYA) announced that results from their Phase 2 study of neoadjuvant darovasertib in primary uveal melanoma will be presented at ESMO 2025 in Berlin. The study includes data from over 90 patients across plaque brachytherapy and enucleation-eligible cohorts.The presentation will highlight darovasertib's potential impact on disease management, particularly notable as it has received FDA Breakthrough Therapy Designation for neoadjuvant use in uveal melanoma patients requiring enucleation. The company has also initiated OptimUM-10, a global Phase 3 neoadjuvant registrational trial, in Q3 2025.

#IDYA IDEAYA Biosciences Announces Proffered Paper Oral Presentation at ESMO 2025 for Phase 2 Clinical Trial of Neoadjuvant Darovasertib in Primary Uveal Melanoma

www.stocktitan.net/news/IDYA/ideaya-bioscie...

IDEAYA Biosciences, Inc. Reports First Quarter 2025 Financial Results and Provides Business Update IDEAYA Biosciences (NASDAQ: IDYA) reported Q1 2025 financial results with $1.05 billion in cash reserves, extending runway into 2029. Key highlights include: Over 300 patients enrolled in darovasertib and crizotinib registrational trial for metastatic uveal melanoma (MUM), with median PFS results targeted by YE 2025. The company received FDA Breakthrough Therapy Designation for darovasertib in neoadjuvant UM treatment. Q1 2025 showed a net loss of $72.2 million, with R&D expenses at $70.9 million and G&A expenses at $13.5 million. IDEAYA's pipeline progress includes IDE849 Phase 1 initiation in the U.S., IDE275 presentation at AACR 2025, and plans for three additional IND filings in 2025 (PRMT5, B7H3/PTK7 ADC, and KAT6/7). The company strengthened its leadership team with new CFO Joshua Bleharski and SVP of Technical Operations Shanthakumar Tyavanagimatt.

#IDYA IDEAYA Biosciences, Inc. Reports First Quarter 2025 Financial Results and Provides Business Update

www.stocktitan.net/news/IDYA/ideaya-bioscie...

Breakthrough Cancer Drug IDE849 Gets FDA Green Light: Early Data Shows Promise in Multiple Tumors Novel DLL3 TOP1 ADC shows partial responses in early trials. Targeting multiple cancer types including SCLC and NETs. See latest trial data.

#IDYA IDEAYA Biosciences Announces US FDA IND-Clearance for IDE849, a Potential First-in-Class DLL3 TOP1 ADC, for a Phase 1 Study in Solid Tumors

www.stocktitan.net/news/IDYA/ideaya-bioscie...

Major FDA Breakthrough: IDEAYA's Eye-Saving Cancer Drug Advances to Phase 3 Trial FDA validates Phase 3 design for darovasertib in uveal melanoma treatment. Breakthrough-designated therapy aims to preserve vision and prevent eye removal.

#IDYA IDEAYA Biosciences Announces Successful FDA Type D Meeting on Phase 3 Registrational Trial Design for Darovasertib as Neoadjuvant Therapy for Primary Uveal Melanoma

www.stocktitan.net/news/IDYA/ideaya-bioscie...

IDEAYA Biosciences Announces Phase 1/2 Expansion for IDE397 and Trodelvy® Combination in MTAP-Deletion Urothelial Cancer IDEAYA Biosciences (IDYA) has initiated a Phase 1/2 expansion study evaluating the combination of IDE397, its MAT2A inhibitor, with Trodelvy® in MTAP-deletion urothelial cancer (UC). The expansion is based on preliminary safety and clinical efficacy data.IDE397 is a potent and selective small molecule inhibitor targeting MAT2A in solid tumors with MTAP-deletion, which affects approximately 26% of UC patients. The combination represents a potential first-in-class treatment approach for MTAP-deletion UC, addressing an unmet medical need with no currently approved targeted therapies.A clinical program update on the IDE397-Trodelvy combination is expected in 2025. Additionally, IDEAYA plans to initiate a combination trial of IDE397 with IDE892, their MTA-cooperative PRMT5 inhibitor, in the second half of 2025.

#IDYA IDEAYA Biosciences Announces Phase 1/2 Expansion for IDE397 and Trodelvy® Combination in MTAP-Deletion Urothelial Cancer

www.stocktitan.net/news/IDYA/ideaya-bioscie...

IDEAYA Leadership to Showcase Ophthalmology and Oncology Progress at Two Elite Conferences CEO and CMO to discuss pipeline developments at RBCCM Ophthalmology and Stifel Oncology forums this April. Live webcasts available. Full schedule inside.

#IDYA IDEAYA Biosciences Announces Participation in Upcoming April 2025 Investor Relations Events

www.stocktitan.net/news/IDYA/ideaya-bioscie...

Revolutionary Eye Cancer Drug Achieves FDA Breakthrough Status: 82% Tumor Shrinkage Rate First-in-class treatment shows 61% eye preservation in melanoma patients. No FDA-approved alternatives exist for 12,000 annual cases. See full clinical data.

#IDYA IDEAYA Biosciences Receives US FDA Breakthrough Therapy Designation for Darovasertib Monotherapy in Neoadjuvant Uveal Melanoma

www.stocktitan.net/news/IDYA/ideaya-bioscie...

Breakthrough Cancer Treatment: IDEAYA's IDE275 Targets Major Tumor Types with GSK Backing New Werner Helicase inhibitor IDE275 demonstrates selective efficacy against MSI-H tumors, potentially treating 31% of endometrial cancers. Full analysis inside.

#IDYA IDEAYA Announces Oral Presentation at the New Drugs on the Horizon Series at AACR 2025 for IDE275 (GSK959), a Phase 1 Werner Helicase Inhibitor

www.stocktitan.net/news/IDYA/ideaya-announc...

Can AI Finally Crack "Undruggable" Cancer Targets? IDEAYA's New Tech Partnership Aims to Revolutionize Oncology IDEAYA teams with ATTMOS to develop AI-powered platform for discovering cancer therapies against previously inaccessible targets, accelerating first-in-class oncology treatments.

#IDYA IDEAYA Biosciences Announces Collaboration with ATTMOS to Accelerate AI/ML-Enabled Drug Discovery for Unprecedented First-in-Class Oncology Targets

www.stocktitan.net/news/IDYA/ideaya-bioscie...

IDEAYA Biosciences, Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update IDEAYA Biosciences reported its Q4 and full-year 2024 financial results, highlighting significant progress across its clinical pipeline. The company ended 2024 with approximately $1.1 billion in cash, cash equivalents, and marketable securities, expected to fund operations into at least 2028.Key developments include over 230 patients enrolled in the registration-enabling trial for darovasertib in metastatic uveal melanoma, with median PFS readout targeted by year-end 2025. The company reported encouraging Phase 1 expansion results for IDE397 in MTAP-deletion cancers and selected clinical expansion doses for DLL3 TOP1i ADC IDE849.Financial highlights for Q4 2024 include collaboration revenue of $7.0 million, R&D expenses of $140.2 million, and a net loss of $130.3 million. The full-year 2024 net loss was $274.5 million.

#IDYA IDEAYA Biosciences, Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

www.stocktitan.net/news/IDYA/ideaya-bioscie...

Major Clinical Trial Update: IDEAYA's Novel Cancer Drug Targets 48,000 Annual NSCLC Cases IDEAYA partners with Gilead Sciences to test IDE397-Trodelvy combination in MTAP-deletion lung cancer, targeting 15% of NSCLC patients in expanded trial.

#IDYA IDEAYA Announces Further Gilead Sciences Clinical Study Collaboration Evaluating Combination of Trodelvy® and IDE397 in MTAP-Deletion NSCLC

www.stocktitan.net/news/IDYA/ideaya-announc...

News; ( NASDAQ: #IDYA ) IDEAYA Biosciences Announces Participation at the 43rd Annual J.P. Morgan Healthcare Conference and 2025 Corporate Guidance

IDEAYA Secures Global Rights to Promising Cancer Drug SHR-4849 with 73% Response Rate in SCLC Trial IDEAYA Biosciences acquires ex-Greater China rights to Hengrui's DLL3-targeting ADC showing strong early efficacy in small cell lung cancer. $75M upfront, $1.045B milestone potential.

#IDYA IDEAYA Biosciences Enters Exclusive License with Hengrui Pharma for SHR-4849, a Novel Phase 1 DLL3 Topo-I-Payload ADC Targeting SCLC and NET Solid Tumors

www.stocktitan.net/news/IDYA/ideaya-bioscie...

IDEAYA's Novel Cancer Drug Shows Promise for Breast & Lung Cancer Treatment IDEAYA Biosciences advances IDE251, a pioneering KAT6/7 inhibitor showing strong preclinical results for breast and lung cancers affecting 15-17.5% of patients.

#IDYA IDEAYA Announces Development Candidate Nomination of IDE251, a Potential First-in-Class KAT6/7 Dual Inhibitor Targeting 8p11 Amplification Tumors in Breast and Lung Cancers

www.stocktitan.net/news/IDYA/ideaya-announc...

IDEAYA Biosciences Unveils Breakthrough Cancer Pipeline at December R&D Day: First-in-Class Therapeutics in Focus Get exclusive insights into IDEAYA's innovative oncology pipeline, featuring groundbreaking drug candidates and expert perspectives from leading cancer research institutions.

#IDYA IDEAYA Announces Agenda for Investor R&D Day Webcast on December 16, 2024

#StockMarket #stocks #investing

www.stocktitan.net/news/IDYA/ideaya-announc...

IDEAYA Biosciences Unveils IDE892, Breakthrough Cancer Drug Candidate with Promising Preclinical Results IDEAYA's new PRMT5 inhibitor IDE892 shows powerful anti-tumor activity in preclinical studies, marking company's 7th development candidate for MTAP-deletion cancers.

#IDYA IDEAYA Biosciences Announces Development Candidate Nomination of IDE892, a Potential Best-in-Class MTA-cooperative PRMT5 Inhibitor

#StockMarket #stocks #investing

www.stocktitan.net/news/IDYA/ideaya-bioscie...

IDEAYA Biosciences to Present at Major Healthcare Conferences in December | IDYA Stock News CEO Yujiro S. Hata to participate in fireside chat at Citi's Healthcare Conference, followed by Evercore HealthCONx presentation. Live webcasts available for investors.

#IDYA IDEAYA Biosciences Announces Participation in Upcoming December 2024 Investor Relations Events

#StockMarket #investing #stocks

www.stocktitan.net/news/IDYA/ideaya-bioscie...

#IDYA IDEAYA Biosciences Appoints Stu Dorman as Chief Commercial Officer

www.stocktitan.net/news/IDYA/ideaya-bioscie...